Literature DB >> 18032593

Serotype-specific and age-dependent generation of pneumococcal polysaccharide-specific memory B-cell and antibody responses to immunization with a pneumococcal conjugate vaccine.

Elizabeth A Clutterbuck1, Sarah Oh, Mainga Hamaluba, Sharon Westcar, Peter C L Beverley, Andrew J Pollard.   

Abstract

Glycoconjugate vaccines have dramatically reduced the incidence of encapsulated bacterial diseases in toddlers under 2 years of age, but vaccine-induced antibody levels in this age group wane rapidly. We immunized adults and 12-month-old toddlers with heptavalent pneumococcal conjugate vaccine to determine differences in B-cell and antibody responses. The adults and 12-month-old toddlers received a pneumococcal conjugate vaccine. The toddlers received a second dose at 14 months of age. The frequencies of diphtheria toxoid and serotype 4, 14, and 23F polysaccharide-specific plasma cells and memory B cells were determined by enzyme-linked immunospot assay. The toddlers had no preexisting polysaccharide-specific memory B cells or serum immunoglobulin G (IgG) antibody but had good diphtheria toxoid-specific memory responses. The frequencies of plasma cells and memory B cells increased by day 7 (P < 0.0001) in the adults and the toddlers following a single dose of conjugate, but the polysaccharide responses were significantly lower in the toddlers than in the adults (P = 0.009 to <0.001). IgM dominated the toddler antibody responses, and class switching to the IgG was serotype dependent. A second dose of vaccine enhanced the antibody and memory B-cell responses in the toddlers but not the ex vivo plasma cell responses. Two doses of pneumococcal conjugate vaccine are required in toddlers to generate memory B-cell frequencies and antibody class switching for each pneumococcal polysaccharide equivalent to that seen in adults.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18032593      PMCID: PMC2238039          DOI: 10.1128/CVI.00336-07

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  81 in total

1.  Delayed and deficient establishment of the long-term bone marrow plasma cell pool during early life.

Authors:  M Pihlgren; N Schallert; C Tougne; P Bozzotti; J Kovarik; A Fulurija; M Kosco-Vilbois; P H Lambert; C A Siegrist
Journal:  Eur J Immunol       Date:  2001-03       Impact factor: 5.532

2.  Booster response to the tetanus and diphtheria toxoid carriers of 11-valent pneumococcal conjugate vaccine in adults and toddlers.

Authors:  R M Olander; T Wuorimaa; H Käyhty; O Leroy; R Dagan; J Eskola
Journal:  Vaccine       Date:  2001-11-12       Impact factor: 3.641

3.  Acute and long-term effects of booster immunisation on frequencies of antigen-specific memory B-lymphocytes.

Authors:  R Nanan; D Heinrich; M Frosch; H W Kreth
Journal:  Vaccine       Date:  2001-11-12       Impact factor: 3.641

4.  Marginal zone and B1 B cells unite in the early response against T-independent blood-borne particulate antigens.

Authors:  F Martin; A M Oliver; J F Kearney
Journal:  Immunity       Date:  2001-05       Impact factor: 31.745

Review 5.  Accessory cell defect in unresponsiveness of neonates and aged to polysaccharide vaccines.

Authors:  S Bondada; H Wu; D A Robertson; R L Chelvarajan
Journal:  Vaccine       Date:  2000-10-15       Impact factor: 3.641

6.  Serotype of Streptococcus pneumoniae capsular polysaccharide can modify the Th1/Th2 cytokine profile and IgG subclass response to pneumococal-CRM(197) conjugate vaccines in a murine model.

Authors:  F Mawas; I M Feavers; M J Corbel
Journal:  Vaccine       Date:  2000-12-08       Impact factor: 3.641

7.  Tolerability and immunogenicity of an 11-valent pneumococcal conjugate vaccine in adults.

Authors:  T Wuorimaa; H Käyhty; O Leroy; J Eskola
Journal:  Vaccine       Date:  2001-02-28       Impact factor: 3.641

8.  IgG subclass switch capacity is low in switched and in IgM-only, but high in IgD+IgM+, post-germinal center (CD27+) human B cells.

Authors:  C Werner-Favre; F Bovia; P Schneider; N Holler; M Barnet; V Kindler; J Tschopp; R H Zubler
Journal:  Eur J Immunol       Date:  2001-01       Impact factor: 5.532

9.  Natural development of antibodies to pneumococcal surface protein A, pneumococcal surface adhesin A, and pneumolysin in relation to pneumococcal carriage and acute otitis media.

Authors:  S Rapola; V Jäntti; R Haikala; R Syrjänen; G M Carlone; J S Sampson; D E Briles; J C Paton; A K Takala; T M Kilpi; H Käyhty
Journal:  J Infect Dis       Date:  2000-09-05       Impact factor: 5.226

10.  Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM(197) among infants with sickle cell disease. Pneumococcal Conjugate Vaccine Study Group.

Authors:  K L O'Brien; A J Swift; J A Winkelstein; M Santosham; B Stover; R Luddy; J E Gootenberg; J T Nold; A Eskenazi; S J Snader; H M Lederman
Journal:  Pediatrics       Date:  2000-11       Impact factor: 7.124

View more
  28 in total

1.  Circulating antibody-secreting cells during acute respiratory syncytial virus infection in adults.

Authors:  F Eun-Hyung Lee; Ann R Falsey; Jessica L Halliley; Iñaki Sanz; Edward E Walsh
Journal:  J Infect Dis       Date:  2010-10-27       Impact factor: 5.226

2.  Effect of cryopreservation of peripheral blood mononuclear cells (PBMCs) on the variability of an antigen-specific memory B cell ELISpot.

Authors:  Johannes Trück; Ruth Mitchell; Amber J Thompson; Begonia Morales-Aza; Elizabeth A Clutterbuck; Dominic F Kelly; Adam Finn; Andrew J Pollard
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

3.  Serum IgM antibodies contribute to high levels of opsonophagocytic activities in toddlers immunized with a single dose of the 9-valent pneumococcal conjugate vaccine.

Authors:  Birgit Simell; Anu Nurkka; Nina Ekström; Noga Givon-Lavi; Helena Käyhty; Ron Dagan
Journal:  Clin Vaccine Immunol       Date:  2012-08-08

4.  Polysaccharide-specific B cell responses to vaccination in humans.

Authors:  Ruth Mitchell; Dominic F Kelly; Andrew J Pollard; Johannes Trück
Journal:  Hum Vaccin Immunother       Date:  2014-03-14       Impact factor: 3.452

5.  Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults: a randomized open-label trial.

Authors:  Christine Juergens; Pierre J T de Villiers; Keymanthri Moodley; Deepthi Jayawardene; Kathrin U Jansen; Daniel A Scott; Emilio A Emini; William C Gruber; Beate Schmoele-Thoma
Journal:  Hum Vaccin Immunother       Date:  2014-02-27       Impact factor: 3.452

6.  Circulating human antibody-secreting cells during vaccinations and respiratory viral infections are characterized by high specificity and lack of bystander effect.

Authors:  F Eun-Hyung Lee; Jessica L Halliley; Edward E Walsh; Andrew P Moscatiello; Brittany L Kmush; Ann R Falsey; Troy D Randall; Denise A Kaminiski; Richard K Miller; Iñaki Sanz
Journal:  J Immunol       Date:  2011-03-25       Impact factor: 5.422

7.  Concomitant administration of Mycobacterium bovis BCG with the meningococcal C conjugate vaccine to neonatal mice enhances antibody response and protective efficacy.

Authors:  Siggeir F Brynjolfsson; Stefania P Bjarnarson; Elena Mori; Giuseppe Del Giudice; Ingileif Jonsdottir
Journal:  Clin Vaccine Immunol       Date:  2011-09-07

8.  Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines.

Authors:  Andrew J Pollard; Kirsten P Perrett; Peter C Beverley
Journal:  Nat Rev Immunol       Date:  2009-03       Impact factor: 53.106

9.  Long-lived antibody and B Cell memory responses to the human malaria parasites, Plasmodium falciparum and Plasmodium vivax.

Authors:  Jiraprapa Wipasa; Chaisuree Suphavilai; Lucy C Okell; Jackie Cook; Patrick H Corran; Kanitta Thaikla; Witaya Liewsaree; Eleanor M Riley; Julius Clemence R Hafalla
Journal:  PLoS Pathog       Date:  2010-02-19       Impact factor: 6.823

10.  Antibody avidity in humoral immune responses in Bangladeshi children and adults following administration of an oral killed cholera vaccine.

Authors:  Mohammad Murshid Alam; Daniel T Leung; Marjahan Akhtar; Mohammad Nazim; Sarmin Akter; Taher Uddin; Farhana Khanam; Deena Al Mahbuba; Shaikh Meshbahuddin Ahmad; Taufiqur Rahman Bhuiyan; Stephen B Calderwood; Edward T Ryan; Firdausi Qadri
Journal:  Clin Vaccine Immunol       Date:  2013-08-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.